Auravax Theurapeutics, Inc. Information

AuraVax Therapeutics, Inc is a privately held biotechnology company developing a proprietary and differentiated platform for vaccination of COVID-19. Our next-generation vaccine platform combines the potential of in-home administration with the ability to deliver complete immunity. The technology has already been validated for COVID-19 in mice and results in immunity measured by both B-cell and T-cell responses. Beyond COVID-19, our approach has application to other serious respiratory pathogens. By design, a single administration of our novel vaccine directly delivers an inert immunogen into the nasal passages and lung, which are common viral entry points for COVID-19. Our technology not only elicits a mucosal immune response, but also systemic immunity.